Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D014226:Triazenes / Q000627:therapeutic use*
D010879:Piperazines; D014226:Triazenes; D011929:Razoxane; D003606:Dacarbazine; D002945:Cisplatin